Novavax's Covid-19 Vaccine 'Covavax' To Launch In India By S
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The Serum Institute of India (SII) hopes to introduce US firm Novavax's Indian version of the Covid-19 vaccine - 'Covavax' by September this year and start trials on children from July, sources said. Novavax's vaccine exhibited a 90.4 percent overall efficacy in Phase-3 clinical trials.

That puts it in the same bracket as two of the frontline vaccines being used in the US and European countries, the ones produced by Pfizer-BioNTech and Moderna, which had efficacy rates of 91.3 per cent and 90 per cent in Phase 3 trials, respectively. Serum Institute plans to start clinical trials of the Novavax shot for Children in July.

The Centre said that recently declared Novavax Covid vaccine efficacy data in a large trial are promising and that clinical trials are being conducted and are in an advanced stage of completion in India. "What we're learning from data available in the public domain that this vaccine is very safe and highly effective. It'll be produced in India," said Dr VK Paul, Member-Health, Niti Aayog said.

He also added that gap in the production of Novavax's vaccine was likely for a while. Novavax's vaccine candidate has partnered with Pune-based vaccine manufacturer Serum Institute of India to produce doses in India.